Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASH Meeting 2016: developments in hemostaseology

ASH Meeting 2016: developments in hemostaseology During the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. One of the highlights of the meeting in this year’s plenary session was the presentation of successful adeno-associated virus mediated gene transfer in patients with hemophilia B leading to sustained elevation of factor IX:C (FIX:c). Other alternative treatment approaches in patients with hemophilia A may include bispecific antibodies mimicking factor VIIIa (FVIIIa) activity or disrupting anticoagulant proteins. Focusing on anticoagulation, data on the use of direct oral anticoagulants (DOACs) in cancer patients with atrial fibrillation as well as treatment of superficial vein thrombosis with rivaroxaban were presented. In this short review, we try to highlight the most important presentations during the ASH meeting 2016. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASH Meeting 2016: developments in hemostaseology

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/ash-meeting-2016-developments-in-hemostaseology-S0w1dziHSq
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0339-z
Publisher site
See Article on Publisher Site

Abstract

During the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. One of the highlights of the meeting in this year’s plenary session was the presentation of successful adeno-associated virus mediated gene transfer in patients with hemophilia B leading to sustained elevation of factor IX:C (FIX:c). Other alternative treatment approaches in patients with hemophilia A may include bispecific antibodies mimicking factor VIIIa (FVIIIa) activity or disrupting anticoagulant proteins. Focusing on anticoagulation, data on the use of direct oral anticoagulants (DOACs) in cancer patients with atrial fibrillation as well as treatment of superficial vein thrombosis with rivaroxaban were presented. In this short review, we try to highlight the most important presentations during the ASH meeting 2016.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 1, 2017

References

  • Spk-9001: adeno-associated virus mediated gene transfer for hemophilia B achieves sustained mean factor IX activity levels of 〉30 % without Immunosuppression; ASH 2016 plenary session #003
    George, LA; Sullivan, SK; Giermasz, A
  • Factor VIII-mimetic function of humanized Bispecific antibody in hemophilia A
    Shima, M; Hanabusa, H; Taki, M
  • Direct oral anticoagulants in patients with cancer. ASH 2016 #877
    Shah, S; Datta, YH; Norby, F
  • Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial
    Beyer-Westendorf, J; Schellong, SM; Gerlach, H
  • Management of superficial vein thrombosis
    Cosmi, B
  • Fondaparinux for the treatment of superficial-vein thrombosis in the legs
    Decousus, H; Prandoni, P; Mismetti, P
  • Lee AY Guidance for the prevention and treatment of cancer-associated venous thromboembolism
    Khorana, AA; Carrier, M; Garcia, DA
  • International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
    Farge, D; Debourdeau, P; Beckers, M
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update
    Lyman, GH; Khorana, AA; Kuderer, NM
  • A randomized trial of factor VIII and neutralizing antibodies in hemophilia A
    Peyvandi, F; Mannucci, PM; Garagiola, I
  • Outcome of clinical trials with new extended half-life FVIII/IX concentrates
    Mancuso, ME; Santagostino, E
  • 2017 Clinical trials update: Innovations in hemophilia therapy
    Hartmann, J; Croteau, SE
  • A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
    Uchida, N; Sambe, T; Yoneyama, K
  • Long-term safety and efficacy of factor IX gene therapy in hemophilia B
    Nathwani, AC; Reiss, UM; Tuddenham, EG
  • High KA Immune responses to AAV in clinical trials
    Mingozzi, F
  • Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors
    Monahan, PE
  • X-linked thrombophilia with a mutant factor IX (factor IX Padua)
    Simioni, P; Tormene, D; Tognin, G